News

December 6, 2019December 6, 2019

Orencia Effective as Stand-alone Therapy in Children With polyarticular JIA, Phase 3 Trial Shows

News

Treatment with Orencia (abatacept) was effective and well-tolerated at four months in children and adolescents with polyarticular juvenile idiopathic arthritis (pJIA) who were intolerant or unresponsive to methotrexate, Phase 3 ... Read more

December 3, 2019December 3, 2019

FDA Approves RediTrex, an Injectable Form of Methotrexate, for JIA Treatment

News

The U.S. Food and Drug Administration (FDA) has approved RediTrex, an injectable form of methotrexate, for the treatment of juvenile idiopathic arthritis (JIA), active rheumatoid arthritis, and severe psoriasis. ... Read more

November 26, 2019November 26, 2019

New Treatments Needed for Children with JIA, Swedish Study Suggests

News

Despite the increasing number of treatments, children with juvenile idiopathic arthritis (JIA) still experience disease activity most of the time, real-world data from Sweden suggest. The findings highlight the ... Read more

November 22, 2019November 22, 2019

New Medications Needed for Children with JIA, Study Reports

News

The common use of off-label treatments and high failure with available biologic therapies shows the need for new medications for children in the United States with juvenile idiopathic arthritis (JIA), ... Read more

November 19, 2019November 19, 2019

FDA Approves Abrilada, Biosimilar to Humira, for JIA and Other Inflammatory Disorders

News

The U. S. Food and Drug Administration (FDA) has approved Abrilada (adalimumab-afzb), a biosimilar to Humira, for the treatment of juvenile idiopathic arthritis (JIA) in patients 4 and older and ... Read more

November 15, 2019November 15, 2019

ADA2 Protein Is Reliable Marker of Macrophage Activation Syndrome in Systemic JIA, Study Suggests

News

Measuring the blood levels of the protein adenosine deaminase 2 (ADA2) accurately identifies macrophage activation syndrome (MAS) in children with systemic juvenile idiopathic arthritis (sJIA), a study suggests. The ... Read more

November 12, 2019November 12, 2019

Xeljanz Eases Symptoms and Disease Flares in Children with Polyarticular JIA, Phase 3 Trial Shows

News

Treatment with Xeljanz (tofacitinib) reduces disease flares, improves physical functioning, and significantly eases symptoms of polyarticular juvenile idiopathic arthritis (pJIA), results from a Phase 3 clinical trial show. The research, ... Read more

November 8, 2019November 8, 2019

Children with JIA at Risk for Depression and Anxiety, Lower Quality of Life, Review Suggests

News

Children with juvenile idiopathic arthritis (JIA) experience anxiety and depression at higher rates than their peers without the condition, which takes a toll on their quality of life, a ... Read more

November 5, 2019

TNF Inhibitors Increase Risk of Psoriasis in JIA Patients, Study Suggests

News

Treatment with TNF inhibitors increases the risk of psoriasis in children with juvenile idiopathic arthritis (JIA) and other inflammatory disorders, a new study reports. The study, “Psoriasis Associated with Tumor Necrosis ... Read more

November 1, 2019November 1, 2019

IL1RN Gene Variants Do Not Affect Response to Kineret or Ilaris in Systemic JIA, German Study Suggests

News

Variants in the gene leading to the protein interleukin-1 receptor antagonist (or IL1RA) do not seem to affect the response of children with systemic juvenile idiopathic arthritis (sJIA) to ... Read more

Pin It on Pinterest